JP2001502883A - ミニアデノウイルスベクター - Google Patents
ミニアデノウイルスベクターInfo
- Publication number
- JP2001502883A JP2001502883A JP09543095A JP54309597A JP2001502883A JP 2001502883 A JP2001502883 A JP 2001502883A JP 09543095 A JP09543095 A JP 09543095A JP 54309597 A JP54309597 A JP 54309597A JP 2001502883 A JP2001502883 A JP 2001502883A
- Authority
- JP
- Japan
- Prior art keywords
- dna molecule
- gene
- protein
- vector
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000013598 vector Substances 0.000 title claims abstract description 425
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 181
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 406
- 238000000034 method Methods 0.000 claims abstract description 118
- 241001465754 Metazoa Species 0.000 claims abstract description 110
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims abstract description 96
- 108700019146 Transgenes Proteins 0.000 claims abstract description 68
- 102000057593 human F8 Human genes 0.000 claims abstract description 67
- 238000011830 transgenic mouse model Methods 0.000 claims abstract description 59
- 238000012360 testing method Methods 0.000 claims abstract description 44
- 238000004519 manufacturing process Methods 0.000 claims abstract description 42
- 238000001727 in vivo Methods 0.000 claims abstract description 38
- 239000003814 drug Substances 0.000 claims abstract description 19
- 208000009292 Hemophilia A Diseases 0.000 claims abstract description 18
- 208000031220 Hemophilia Diseases 0.000 claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims description 366
- 108020004414 DNA Proteins 0.000 claims description 348
- 102000053602 DNA Human genes 0.000 claims description 224
- 230000014509 gene expression Effects 0.000 claims description 218
- 238000004806 packaging method and process Methods 0.000 claims description 216
- 102000004169 proteins and genes Human genes 0.000 claims description 188
- 241000700605 Viruses Species 0.000 claims description 125
- 101001000998 Homo sapiens Protein phosphatase 1 regulatory subunit 12C Proteins 0.000 claims description 118
- 102100035620 Protein phosphatase 1 regulatory subunit 12C Human genes 0.000 claims description 118
- 239000013612 plasmid Substances 0.000 claims description 107
- 230000010354 integration Effects 0.000 claims description 103
- 239000005090 green fluorescent protein Substances 0.000 claims description 87
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 86
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 77
- 239000012634 fragment Substances 0.000 claims description 70
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims description 66
- 208000015181 infectious disease Diseases 0.000 claims description 62
- 241001135569 Human adenovirus 5 Species 0.000 claims description 61
- 230000009261 transgenic effect Effects 0.000 claims description 61
- 230000010076 replication Effects 0.000 claims description 55
- 238000003752 polymerase chain reaction Methods 0.000 claims description 54
- 239000012636 effector Substances 0.000 claims description 51
- 230000000694 effects Effects 0.000 claims description 46
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 45
- 238000012217 deletion Methods 0.000 claims description 43
- 230000037430 deletion Effects 0.000 claims description 43
- 210000001519 tissue Anatomy 0.000 claims description 42
- 230000027455 binding Effects 0.000 claims description 41
- 239000002245 particle Substances 0.000 claims description 41
- 210000004185 liver Anatomy 0.000 claims description 40
- 108700008625 Reporter Genes Proteins 0.000 claims description 35
- 241000699660 Mus musculus Species 0.000 claims description 30
- 230000002458 infectious effect Effects 0.000 claims description 30
- 108010088751 Albumins Proteins 0.000 claims description 29
- 230000001105 regulatory effect Effects 0.000 claims description 28
- 239000006166 lysate Substances 0.000 claims description 26
- 238000012423 maintenance Methods 0.000 claims description 26
- 230000006798 recombination Effects 0.000 claims description 26
- 238000005215 recombination Methods 0.000 claims description 26
- 230000003612 virological effect Effects 0.000 claims description 26
- 102000009027 Albumins Human genes 0.000 claims description 24
- 210000002459 blastocyst Anatomy 0.000 claims description 23
- 230000002950 deficient Effects 0.000 claims description 23
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 22
- 241000701022 Cytomegalovirus Species 0.000 claims description 21
- 239000003623 enhancer Substances 0.000 claims description 21
- 150000007523 nucleic acids Chemical class 0.000 claims description 21
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 20
- 230000004543 DNA replication Effects 0.000 claims description 19
- 239000003550 marker Substances 0.000 claims description 19
- 239000013603 viral vector Substances 0.000 claims description 19
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 18
- 101150024821 tetO gene Proteins 0.000 claims description 18
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims description 17
- 238000004458 analytical method Methods 0.000 claims description 17
- 230000006801 homologous recombination Effects 0.000 claims description 17
- 238000002744 homologous recombination Methods 0.000 claims description 17
- 102000039446 nucleic acids Human genes 0.000 claims description 17
- 108020004707 nucleic acids Proteins 0.000 claims description 17
- 239000002753 trypsin inhibitor Substances 0.000 claims description 16
- 229930193140 Neomycin Natural products 0.000 claims description 15
- 229960004927 neomycin Drugs 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 13
- 230000003313 weakening effect Effects 0.000 claims description 13
- 108020005091 Replication Origin Proteins 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 210000005228 liver tissue Anatomy 0.000 claims description 11
- 238000011144 upstream manufacturing Methods 0.000 claims description 11
- 108700026220 vif Genes Proteins 0.000 claims description 11
- 241000702421 Dependoparvovirus Species 0.000 claims description 10
- 101150029662 E1 gene Proteins 0.000 claims description 10
- 230000002829 reductive effect Effects 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 230000004913 activation Effects 0.000 claims description 8
- 230000000384 rearing effect Effects 0.000 claims description 8
- 230000029812 viral genome replication Effects 0.000 claims description 8
- 102000009661 Repressor Proteins Human genes 0.000 claims description 6
- 108010034634 Repressor Proteins Proteins 0.000 claims description 6
- 238000009395 breeding Methods 0.000 claims description 6
- 230000001488 breeding effect Effects 0.000 claims description 6
- 230000002441 reversible effect Effects 0.000 claims description 6
- 101710091045 Envelope protein Proteins 0.000 claims description 5
- 102100034349 Integrase Human genes 0.000 claims description 5
- 101710188315 Protein X Proteins 0.000 claims description 5
- 101150066038 E4 gene Proteins 0.000 claims description 4
- 108010031111 EBV-encoded nuclear antigen 1 Proteins 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 210000000170 cell membrane Anatomy 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000002759 chromosomal effect Effects 0.000 claims description 4
- 238000000799 fluorescence microscopy Methods 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 210000003240 portal vein Anatomy 0.000 claims description 4
- 230000036961 partial effect Effects 0.000 claims description 3
- 102000055501 telomere Human genes 0.000 claims description 3
- 108091035539 telomere Proteins 0.000 claims description 3
- 210000003411 telomere Anatomy 0.000 claims description 3
- 210000003462 vein Anatomy 0.000 claims description 3
- 238000007901 in situ hybridization Methods 0.000 claims description 2
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 claims 14
- 108010054218 Factor VIII Proteins 0.000 abstract description 114
- 102000001690 Factor VIII Human genes 0.000 abstract description 108
- 229960000301 factor viii Drugs 0.000 abstract description 106
- 239000002299 complementary DNA Substances 0.000 abstract description 48
- 238000013461 design Methods 0.000 abstract description 33
- 238000001415 gene therapy Methods 0.000 abstract description 30
- 210000002443 helper t lymphocyte Anatomy 0.000 abstract description 21
- 238000012546 transfer Methods 0.000 abstract description 18
- 230000002068 genetic effect Effects 0.000 abstract description 10
- 238000002255 vaccination Methods 0.000 abstract description 4
- 238000011156 evaluation Methods 0.000 abstract description 3
- 230000008093 supporting effect Effects 0.000 abstract description 2
- 206010028980 Neoplasm Diseases 0.000 description 38
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 38
- 239000000047 product Substances 0.000 description 34
- 108020005202 Viral DNA Proteins 0.000 description 27
- 230000000120 cytopathologic effect Effects 0.000 description 26
- 230000028993 immune response Effects 0.000 description 24
- 230000007246 mechanism Effects 0.000 description 24
- 239000000523 sample Substances 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 23
- 238000010276 construction Methods 0.000 description 23
- 230000003321 amplification Effects 0.000 description 21
- 238000003199 nucleic acid amplification method Methods 0.000 description 21
- 230000001225 therapeutic effect Effects 0.000 description 21
- 238000001890 transfection Methods 0.000 description 19
- 238000002105 Southern blotting Methods 0.000 description 18
- 230000012010 growth Effects 0.000 description 18
- 238000010171 animal model Methods 0.000 description 17
- 238000013459 approach Methods 0.000 description 17
- 201000011510 cancer Diseases 0.000 description 17
- 238000013518 transcription Methods 0.000 description 16
- 230000035897 transcription Effects 0.000 description 16
- 238000011282 treatment Methods 0.000 description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 238000010361 transduction Methods 0.000 description 14
- 210000004881 tumor cell Anatomy 0.000 description 14
- 102000018120 Recombinases Human genes 0.000 description 13
- 108010091086 Recombinases Proteins 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 230000004048 modification Effects 0.000 description 13
- 238000012986 modification Methods 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 230000026683 transduction Effects 0.000 description 13
- 108091026890 Coding region Proteins 0.000 description 12
- 230000001093 anti-cancer Effects 0.000 description 12
- 238000001476 gene delivery Methods 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 101100524324 Adeno-associated virus 2 (isolate Srivastava/1982) Rep78 gene Proteins 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- 210000000234 capsid Anatomy 0.000 description 11
- 238000010367 cloning Methods 0.000 description 11
- 230000036039 immunity Effects 0.000 description 11
- 102100039556 Galectin-4 Human genes 0.000 description 10
- 230000029087 digestion Effects 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 9
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 210000003494 hepatocyte Anatomy 0.000 description 9
- 238000000520 microinjection Methods 0.000 description 9
- 230000002688 persistence Effects 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 230000002103 transcriptional effect Effects 0.000 description 9
- 108091029865 Exogenous DNA Proteins 0.000 description 8
- 239000004098 Tetracycline Substances 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000014759 maintenance of location Effects 0.000 description 8
- 230000008685 targeting Effects 0.000 description 8
- 229960002180 tetracycline Drugs 0.000 description 8
- 229930101283 tetracycline Natural products 0.000 description 8
- 235000019364 tetracycline Nutrition 0.000 description 8
- 150000003522 tetracyclines Chemical class 0.000 description 8
- 239000011543 agarose gel Substances 0.000 description 7
- 230000002238 attenuated effect Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 238000010348 incorporation Methods 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 6
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 108010005774 beta-Galactosidase Proteins 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- 210000000349 chromosome Anatomy 0.000 description 6
- 238000012761 co-transfection Methods 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 230000008707 rearrangement Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108010072151 Agouti Signaling Protein Proteins 0.000 description 5
- 102000006822 Agouti Signaling Protein Human genes 0.000 description 5
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 5
- 241000484025 Cuniculus Species 0.000 description 5
- 230000004568 DNA-binding Effects 0.000 description 5
- 108010067770 Endopeptidase K Proteins 0.000 description 5
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 5
- 238000010222 PCR analysis Methods 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 108091023040 Transcription factor Proteins 0.000 description 5
- 102100033254 Tumor suppressor ARF Human genes 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 210000004602 germ cell Anatomy 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000001506 immunosuppresive effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 210000001161 mammalian embryo Anatomy 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 239000013600 plasmid vector Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 239000013607 AAV vector Substances 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102100026735 Coagulation factor VIII Human genes 0.000 description 4
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 201000003542 Factor VIII deficiency Diseases 0.000 description 4
- 102000013462 Interleukin-12 Human genes 0.000 description 4
- 108010065805 Interleukin-12 Proteins 0.000 description 4
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 4
- 108700020796 Oncogene Proteins 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 230000006023 anti-tumor response Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 239000001506 calcium phosphate Substances 0.000 description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 description 4
- 235000011010 calcium phosphates Nutrition 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 230000013020 embryo development Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229960000900 human factor viii Drugs 0.000 description 4
- 230000002519 immonomodulatory effect Effects 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000013605 shuttle vector Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 108090000565 Capsid Proteins Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010014173 Factor X Proteins 0.000 description 3
- 108010003471 Fetal Proteins Proteins 0.000 description 3
- 102000004641 Fetal Proteins Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 3
- 102000048850 Neoplasm Genes Human genes 0.000 description 3
- 108700019961 Neoplasm Genes Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 3
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 3
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000002306 biochemical method Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000010370 cell cloning Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 3
- 238000001976 enzyme digestion Methods 0.000 description 3
- 238000012869 ethanol precipitation Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 102000056549 human Fv Human genes 0.000 description 3
- 108700005872 human Fv Proteins 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000000053 physical method Methods 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 230000010474 transient expression Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 230000005760 tumorsuppression Effects 0.000 description 3
- 238000005199 ultracentrifugation Methods 0.000 description 3
- 101100524319 Adeno-associated virus 2 (isolate Srivastava/1982) Rep52 gene Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000218645 Cedrus Species 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 206010068051 Chimerism Diseases 0.000 description 2
- 108020004638 Circular DNA Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102100024462 Cyclin-dependent kinase 4 inhibitor B Human genes 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 2
- 101710096438 DNA-binding protein Proteins 0.000 description 2
- 102000004237 Decorin Human genes 0.000 description 2
- 108090000738 Decorin Proteins 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101150066002 GFP gene Proteins 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 101000980919 Homo sapiens Cyclin-dependent kinase 4 inhibitor B Proteins 0.000 description 2
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 2
- 101001043807 Homo sapiens Interleukin-7 Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 101150062179 II gene Proteins 0.000 description 2
- 101150098499 III gene Proteins 0.000 description 2
- 101710125507 Integrase/recombinase Proteins 0.000 description 2
- 108091029795 Intergenic region Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 241000824268 Kuma Species 0.000 description 2
- 101710192606 Latent membrane protein 2 Proteins 0.000 description 2
- 102100025169 Max-binding protein MNT Human genes 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 208000009905 Neurofibromatoses Diseases 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 101710150114 Protein rep Proteins 0.000 description 2
- 108700005075 Regulator Genes Proteins 0.000 description 2
- 101710152114 Replication protein Proteins 0.000 description 2
- 108010052160 Site-specific recombinase Proteins 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 101710109576 Terminal protein Proteins 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000010170 biological method Methods 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 108010006025 bovine growth hormone Proteins 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000010307 cell transformation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 238000009402 cross-breeding Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000008571 general function Effects 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 108060003196 globin Proteins 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 102000046157 human CSF2 Human genes 0.000 description 2
- 102000052622 human IL7 Human genes 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004779 membrane envelope Anatomy 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 201000008026 nephroblastoma Diseases 0.000 description 2
- 201000004931 neurofibromatosis Diseases 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 238000012858 packaging process Methods 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000013341 scale-up Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000001608 teratocarcinoma Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 108091006107 transcriptional repressors Proteins 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 238000011820 transgenic animal model Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- CNNSWSHYGANWBM-UHFFFAOYSA-N 6-chloro-2,3-dimethylquinoxaline Chemical compound C1=C(Cl)C=C2N=C(C)C(C)=NC2=C1 CNNSWSHYGANWBM-UHFFFAOYSA-N 0.000 description 1
- MYLBTCQBKAKUTJ-UHFFFAOYSA-N 7-methyl-6,8-bis(methylsulfanyl)pyrrolo[1,2-a]pyrazine Chemical compound C1=CN=CC2=C(SC)C(C)=C(SC)N21 MYLBTCQBKAKUTJ-UHFFFAOYSA-N 0.000 description 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 1
- 101100524321 Adeno-associated virus 2 (isolate Srivastava/1982) Rep68 gene Proteins 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 108700026758 Adenovirus hexon capsid Proteins 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 241000243290 Aequorea Species 0.000 description 1
- 241001248697 Alaudidae Species 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 101150045895 Apela gene Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 108700003860 Bacterial Genes Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108010084313 CD58 Antigens Proteins 0.000 description 1
- 101100279860 Caenorhabditis elegans epg-2 gene Proteins 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 101710199711 Early E1A protein Proteins 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000702191 Escherichia virus P1 Species 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010001515 Galectin 4 Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101150032643 IVa2 gene Proteins 0.000 description 1
- 241000519695 Ilex integra Species 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 206010068052 Mosaicism Diseases 0.000 description 1
- 101100060131 Mus musculus Cdk5rap2 gene Proteins 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101710173835 Penton protein Proteins 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 108020005161 RNA Caps Proteins 0.000 description 1
- 241000282806 Rhinoceros Species 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 241001279158 Silonia silondia Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 206010042573 Superovulation Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000005904 anticancer immunity Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004952 blastocoel Anatomy 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000003169 complementation method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000000448 cultured tumor cell Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000010502 episomal replication Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- -1 flavorings Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000011239 genetic vaccination Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 229960000027 human factor ix Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000008531 maintenance mechanism Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 108700039855 mouse a Proteins 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 101150050780 nodal gene Proteins 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000006548 oncogenic transformation Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 238000012753 partial hepatectomy Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 101150066583 rep gene Proteins 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 102000023888 sequence-specific DNA binding proteins Human genes 0.000 description 1
- 108091008420 sequence-specific DNA binding proteins Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020083 shōchū Nutrition 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 101150061166 tetR gene Proteins 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000037426 transcriptional repression Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005851 tumor immunogenicity Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000006490 viral transcription Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000011816 wild-type C57Bl6 mouse Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/20—Animal model comprising regulated expression system
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/38—Vector systems having a special element relevant for transcription being a stuffer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
- C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Environmental Sciences (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Animal Husbandry (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. アデノウイルス逆末端反復(ITR)、パッケージ化シグナル、転写制御 領域、エフェクター又はレポーター遺伝子、及びゲノム組み込み配列又はエピソ ーム維持配列のいずれかを含み、これらの全てが感染性複製不全組換えアデノウ イルスベクターの生成に作用的に関連する単離DNA分子であって、該DNA分 子の残部はアデノウイルスタンパク質をコードしない単離DNA分子。 2. 前記ゲノム組み込み配列が相同組換えアームを含む、請求項1に記載の単 離DNA分子。 3. 前記相同組換えアームがアルブミンゲノム配列及びα−胎児タンパク質ゲ ノム配列からなる群より選択される、請求項2に記載の単離DNA分子。 4. 前記相同組換えアームがAlb−E5、AFP−3、又はEBB14から なる群より選択される、請求項1に記載の単離DNA分子。 5. 前記ゲノム組換え配列がアデノ関連ウイルス逆末端反復(AAV−ITR )を含む、請求項1に記載の単離DNA分子。 6. 前記エピソーム維持配列がヒトDNA複製基点配列を含む、請求項1に記 載の単離DNA分子。 7. ヒトテロメア配列をさらに含み、かつ前記エピソーム維持配列がヒトDN A複製基点配列を含む、請求項1に記載の単離DNA分子。 8. 前記エピソーム維持配列がアルフォイドDNAを含む、請求項1に記載の 単離DNA分子。 9. 前記エピソーム維持配列がウイルス複製基点及び該ウイルス複製基点の活 性化に必要なタンパク質をコードするヌクレオチド配列を含む、請求項1に記載 の単離DNA分子。 10. 前記エピソーム維持配列がSV40複製基点及びT抗原(T−Ag)を コードする遺伝子を含む、請求項1に記載の単離DNA分子。 11. 前記エピソーム維持配列がウイルス複製基点oriP及びEBNA−1 をコードする遺伝子を含む、請求項1に記載の単離DNA分子。 12. 前記転写制御領域がヒトアルブミンプロモーターを含む、請求項1に記 載の単離DNA分子。 13. 前記転写制御領域がα1−抗トリプシンプロモーターを含む、請求項1 に記載の単離DNA分子。 14. 前記転写制御領域が肝臓特異的エンハンサーを含む、請求項1に記載の 単離DNA分子。 15. 前記転写制御領域がα−抗トリプシンプロモーターに作動可能に連結す る肝臓特異的エンハンサーを含む、請求項1に記載の単離DNA分子。 16. 前記転写制御領域がサイトメガロウイルスプロモーター(CMV)に作 動可能に連結するtet−オペロン(tetO)を含む、請求項1に記載の単離 DNA分子。 17. 前記レポーター遺伝子が緑色蛍光タンパク質をコードする、請求項1に 記載の単離DNA分子。 18. 前記エフェクター遺伝子がFVIII様活性を有するタンパク質をコー ドする、請求項1に記載の単離DNA分子。 19. 前記エフェクター遺伝子がヒトFVIIIをコードする、請求項1に記 載の単離DNA分子。 20. 前記アデノウイルスITRがアデノウイルス5型(Ad5)右ITR及 びAd5左逆末端反復を含む、請求項1に記載の単離DNA分子。 21. 前記アデノウイルス逆末端反復がAd5右ITR及びAd5左ITRを 含み、前記転写制御領域がヒトアルブミンプロモーターを含み、かつ前記エフェ クター遺伝子がFVIII様活性を有するタンパク質をコードする、請求項1に 記載の単離DNA分子。 22. 前記アデノウイルス逆末端反復がAd5右ITR及びAd5左ITRを 含み、前記転写制御領域がヒトアルブミンプロモーターを含み、かつ前記エフェ クター遺伝子がヒトFVIIIをコードする、請求項1に記載の単離DNA分子 。 23. 前記パッケージ化シグナルがパッケージ化の足場点を含む、請求項1に 記載の単離DNA分子。 24. 複数のパッケージ化シグナルを含む、請求項1に記載の単離DNA分子 。 25. 複数の合成パッケージ化シグナルを含む、請求 項1に記載の単離DNA分子。 26. 標的細胞膜に結合することが可能な改変Adエンベロープタンパク質を コードする遺伝子をさらに含む、請求項1に記載の単離DNA分子。 27. 野生型の遺伝子産生物と比較した場合に変更された機能又は構造を有す る遺伝子産生物をコードする改変アデノウイルス遺伝子をさらに含む、請求項1 に記載の単離DNA分子。 28. 転写制御領域に作動可能に連結するE4遺伝子をさらに含む、請求項1 に記載の単離DNA分子。 29. 上流及び下流にAAV−ITRが隣接するレポーター又はエフェクター 遺伝子カセットを含む、感染性複製不全組換えアデノウイルスベクターの生成に 有用な単離DNA分子。 30. 前記レポーター遺伝子が緑色蛍光タンパク質をコードする、請求項1に 記載の単離DNA分子。 31. 前記エフェクター遺伝子がネオマイシン耐性遺伝子、FVIII様活性 を有するタンパク質をコードする遺伝子、及びヒトFVIIIタンパク質をコー ドする核酸からなる群より選択される、請求項29に記載の単離DNA分子。 32. アデノウイルスITR配列、パッケージ化シグナル、AAV ITR配 列、転写制御領域、レポーター又はエフェクター遺伝子、及びRep発現カセッ トを含み、これらの全てが感染性複製不全組換えアデノウイル スベクターの生成に作用的に関連する単離DNA分子であって、該DNA分子の 残部はアデノウイルスタンパク質をコードしない単離DNA分子。 33. 前記レポーター遺伝子が緑色蛍光タンパク質をコードする、請求項32 に記載の単離DNA分子。 34. 前記エフェクター遺伝子がネオマイシン耐性遺伝子、FVIII様活性 を有するタンパク質をコードする遺伝子、及びヒトFVIIIタンパク質をコー ドする遺伝子からなる群より選択される、請求項32に記載の単離DNA分子。 35. 前記転写制御領域がヒトアルブミンプロモーターを含む、請求項32に 記載の単離DNA分子。 36. 前記転写制御領域がα1−抗トリブシンプロモーターを含む、請求項3 2に記載の単離DNA分子。 37. 前記転写制御領域が肝臓特異的エンハンサーを含む、請求項32に記載 の単離DNA分子。 38. 前記転写制御領域がα1−抗トリプシンプロモーターに作動可能に連結 する肝臓特異的エンハンサーを含む、請求項32に記載の単離DNA分子。 39. 前記転写制御領域がサイトメガロウイルスプロモーター(CMV)に作 動可能に連結するtet−オペロン(tetO)を含む、請求項32に記載の単 離DNA分子。 40. 前記パッケージ化シグナルがパッケージ化の足場点を含む、請求項32 に記載の単離DNA分子。 41. 複数のパッケージ化シグナルを含む、請求項32に記載の単離DNA分 子。 42. 複数の合成パッケージ化シグナルを含む、請求項32に記載の単離DN A分子。 43. 標的細胞膜に結合することが可能な改変Adエンベロープタンパク質を コードする遺伝子をさらに含む、請求項32に記載の単離DNA分子。 44. 野生型の遺伝子産生物と比較した場合に変更された機能又は構造を有す る遺伝子産生物をコードする改変アデノウイルス遺伝子をさらに含む、請求項3 2に記載の単離DNA分子。 45. 転写制御領域に作動可能に連結するE4遺伝子をさらに含む、請求項3 2に記載の単離DNA分子。 46. E1欠失ヘルパーAdゲノムを含む単離DNA分子であって、該E1欠 失ヘルパーAdゲノムが野生型ヘルパーAdゲノムよりも低い頻度でパッケージ 化されるように変更されたパッケージ化シグナルを該E1欠失ヘルパーAdゲノ ムが含む単離DNA分子。 47. 前記弱力化パッケージ化シグナルがアデノ富化モチーフ(A反復)の部 分的な欠失を含む、請求項46に記載の単離DNA分子。 48. 前記弱力化パッケージ化シグナルが、該弱力化パッケージ化シグナルに 対するパッケージ化タンパク質の親和性が低下するように直接反復を含む、請求 項46に記載の単離DNA分子。 49. 前記弱力化パッケージ化シグナルが、該弱力化パッケージ化シグナルに 対するパッケージ化タンパク質の親和性が低下するようにA反復配列の直列反復 を含む、請求項46に記載の単離DNA分子。 50. 請求項46に記載の単離DNA分子であって、前記弱力化パッケージ化 シグナルが該DNA分子上のタンパク結合部位に隣接して位置し、それにより該 タンパク質の該タンパク結合部位への結合がパッケージ化タンパク質と該弱力化 パッケージ化シグナルとの会合を妨げる単離DNA分子。 51. 前記パッケージ化シグナルが前記E1欠失ヘルパーAdゲノム内の野生 型ヘルパーAdゲノムに見出されるもの以外の位置に位置する、請求項46に記 載の単離DNA分子。 52. 前記パッケージ化シグナルが、パッケージ化タンパク質に対する親和性 が野生型パッケージ化タンパク質よりも低い合成パッケージ化シグナルである、 請求項46に記載の単離DNA分子。 53. 前記アデノウイルスゲノムがE1に加えてアデノウイルス遺伝子の欠失 を含む、請求項46に記載の単離DNA分子。 54. Ad E1遺伝子配列を含むDNA分子が安定に形質移入されている細 胞であって、該配列がE1欠失ヘルパーAdゲノムのゲノムと重複する配列を持 たない細胞。 55. 組換えアデノウイルスベクターを生成する方法であって、 E1欠失ヘルパーAdゲノムのゲノムと重複する配列を持たないAd E1遺 伝子配列を含むDNA分子が安定に形質移入されている細胞に、アデノウイルス 逆末端反復(ITR)、パッケージ化シグナル、転写制御領域、エフェクター又 はレポーター遺伝子、及びゲノム組み込み配列又はエピソーム維持配列のいずれ かを含み、これらの全てが感染性複製不全組換えアデノウイルスベクターの生成 に作用的に関連する第1単離DNA分子であって、該DNA分子の残部はアデノ ウイルスタンパク質をコードしない第1単離DNA分子、並びにAdヘルパーゲ ノムを含む第2単離DNA分子を同時形質移入する工程; 該細胞の細胞非含有溶解物を調製する工程; を組み合わせてなり、 該細胞非含有溶解物が、該第1DNA分子を含む感染性複製障害組換えアデノ ウイルスベクター粒子を含む方法。 56. 組換えアデノウイルスベクターを生成する方法であって、 E1欠失ヘルパーAdゲノムのゲノムと重複する配列を持たないAd E1遺 伝子配列を含むDNA分子が安定に形質移入されている細胞に、アデノウイルス 逆末端反復(ITR)、パッケージ化シグナル、転写制御領域、 エフェクター又はレポーター遺伝子、及びゲノム組み込み配列又はエピソーム維 持配列のいずれかを含み、これらの全てが感染性複製不全組換えアデノウイルス ベクターの生成に作用的に関連する単離DNA分子であって、該DNA分子の残 部はアデノウイルスタンパク質をコードしない単離DNA分子を形質移入する工 程; 該細胞を、Adヘルパーゲノムを含むAdヘルパーウイルスに感染させる工程 ;及び 該細胞の細胞非含有溶解物を調製する工程; を組み合わせてなり、 該細胞非含有溶解物が、該DNA分子を含む感染性複製障害組換えアデノウイ ルスベクター粒子を含む方法。 57. 前記DNA分子がAAV−ITR及びRep発現カセットをさらに含む 、請求項55又は56による方法。 58. 前記DNA分子がAAV−ITR及びRep発現カセットをさらに含み 、かつ前記細胞がtet−KRABリプレッサータンパク質を発現する、請求項 55又は56項による方法。 59. 前記転写制御領域が前記細胞内よりも標的細胞内においてより活性であ る、請求項55又は56による方法。 60. 前記転写制御領域が肝臓特異的エンハンサー/α−抗トリプシンプロモ ーター;及びtetO/CMVプロモーターからなる群より選択され、前記細胞 がte t−KRABリプレッサータンパク質を発現する、請求項55又は56による方 法。 61. 前記レポーター遺伝子が緑色蛍光タンパク質をコードする、請求項55 又は56による方法。 62. 前記エフェクター遺伝子がネオマイシン耐性遺伝子、FVIII様活性 を有するタンパク質をコードする遺伝子、又はヒトFVIII遺伝子からなる群 より選択される、請求項55又は56による方法。 63. 前記DNA分子がGT2063と呼ばれるプラスミドである、請求項5 5又は56による方法。 64. アデノウイルス逆末端反復(ITR)、パッケージ化シグナル、転写制 御領域、エフェクター又はレポーター遺伝子、及びゲノム組み込み配列又はエピ ソーム維持配列のいずれかを含み、これらの全てが感染性複製不全組換えアデノ ウイルスベクターの生成に作用的に関連するDNA分子を含む組換えアデノウイ ルス粒子であって、該DNA分子の残部はアデノウイルスタンパク質をコードし ない組換えアデノウイルス粒子。 65. 前記レポーター遺伝子が緑色蛍光タンパク質をコードする、請求項64 に記載の組換えアデノウイルス粒子。 66. 前記エフェクター遺伝子がネオマイシン耐性遺伝子、FVIII様活性 を有するタンパク質、及びヒトFVIIIをコードする、請求項64に記載の組 換えアデノウイルス粒子。 67. 前記DNA分子がGT2063である、請求項64に記載の組換えアデ ノウイルス粒子。 68. 前記DNA分子がAAV−ITR及びRep発現カセットをさらに含む 、請求項64に記載の組換えアデノウイルス粒子。 69. アデノウイルス逆末端反復(ITR)、パッケージ化シグナル、転写制 御領域、エフェクター又はレポーター遺伝子、及びゲノム組み込み配列又はエピ ソーム維持配列のいずれかを含み、これらの全てが感染性複製不全組換えアデノ ウイルスベクターの生成に作用的に関連するDNA分子を生理学的に許容し得る バッファ中に含む医薬組成物であって、該DNA分子の残部はアデノウイルスタ ンパク質をコードしない医薬組成物。 70. 前記レポーター遺伝子が緑色蛍光タンパク質をコードする、請求項69 に記載の医薬組成物。 71. 前記エフェクター遺伝子がネオマイシン耐性遺伝子、FVIII様活性 を有するタンパク質をコードする遺伝子、及びヒトFVIII遺伝子からなる群 より選択される、請求項69に記載の医薬組成物。 72. 前記DNA分子がGT2063である、請求項69に記載の医薬組成物 。 73. 治療上有効な量の請求項69に記載の医薬組成物を患者に投与すること を包含する、血友病の治療方法。 74. 非ヒトトランスジェニック動物の生成方法であって、 胚幹細胞に、AAVS1配列及び薬剤選択マーカー遺伝子を含むDNA分子を 形質移入する工程; 該薬剤選択マーカー遺伝子の発現により耐性が付与される薬剤の存在下におい て成長させることにより、そのゲノム内に該DNA分子を含む胚幹細胞を選択す る工程, 該胚幹細胞を胚盤胞に微量注入する工程; 該胚盤胞を仮母に移植する工程; 得られた子孫を飼育する工程; 該子孫をAAVS1配列の存在について検定する工程;及び AAVS1配列が検出されている子孫をホモ接合まで飼育する工程; を組み合わせて包含し、 それによりそのゲノムにAAVS1配列が組み込まれているトランスジェニッ ク動物が生じる方法。 75. 前記非ヒトトランスジェニック動物がマウスである、請求項74に記載 の方法。 76. 前記DNA分子が図52に示されるpAAVS1−Neoである、請求 項74に記載の方法。 77. そのゲノムに安定に組み込まれているAAVS1配列を有する非ヒトト ランスジェニック動物。 78. そのゲノムに安定に組み込まれているAAVS1配列を有する非ヒトト ランスジェニック動物であって、該動物がマウスである非ヒトトランスジェニッ ク動物。 79. 前記動物が、該動物のゲノムに安定に組み込まれている、FVIII様 活性を有するタンパク質をコードする遺伝子をさらに有する、請求項78に記載 の非ヒトトランスジェニック動物。 80. 前記動物が、該動物のゲノムに安定に組み込まれている、ヒトFVII Iをコードする核酸をさらに有する、請求項78に記載の非ヒトトランスジェニ ック動物。 81. 前記動物が血友病表現型、及び該動物のゲノムに安定に組み込まれてい る、FVIII様活性を有するタンパク質をコードする遺伝子を有する、請求項 78に記載の非ヒトトランスジェニック動物。 82. 前記動物が血友病表現型及び該動物のゲノムに安定に組み込まれている ヒトFVIII遺伝子を有する、請求項78に記載の非ヒトトランスジェニック 動物。 83. そのゲノムに安定に組み込まれているDNA分子pAAVS1−Neo 又はそれらの断片を有する、非ヒトトランスジェニックマウス。 84. 前記動物がマウスである、請求項83に記載の非ヒトトランスジェニッ ク動物。 85. そのゲノムにAAVS1配列が組み込まれている非ヒトトランスジェニ ック動物への、AAV−ITRを含むウイルスベクターのイン・ビボ送達を試験 するための方法であって、 生理学的に許容し得るバッファ中の、AAV−ITR 配列を有するDNA分子を含み、かつレポーター又はエフェクター遺伝子をコー ドするベクターを該動物の静脈内又は門脈に注射する工程; 該動物から複数の血液試料を得る工程; 該血液試料における遺伝子発現の水準を測定して導入遺伝子の発現の持続を決 定する工程;及び 該動物の肝臓組織からゲノムDNAを単離する工程;及び AAVS1特異的プライマーを用いて該組織のポリメラーゼ連鎖反応(PCR )分析を行って該動物のゲノムへの該ベクターの組み込みを検出する工程; を組み合わせて包含する方法。 86. 前記ゲノムDNAに対する蛍光インサイツ・ハイブリダイゼーション分 析を行って、前記AAVS1配列の染色***置を決定し、かつ前記AAVS1配 列での前記レポーター又はエフェクター遺伝子の組み込みを検出する工程をさら に含む、請求項85に記載の方法。 87. 前記DNA分子がアデノウイルスITR配列、AAV ITR配列、転 写制御領域、レポーター又はエフェクター遺伝子、及びRep発現カセットを含 み、これらの全てが感染性複製不全組換えアデノウイルスベクターの生成に作用 的に関連し、該DNA分子の残部はアデノウイルスタンパク質をコードしない、 請求項85に記載の方法。 88. 前記DNA分子がアデノウイルスITR配列、 AAV ITR配列、転写制御領域、FVIII様活性を有するタンパク質をコ ードする遺伝子、及びRep発現カセットを含み、これらの全てが感染性複製不 全組換えアデノウイルスベクターの生成に作用的に関連し、該DNA分子の残部 はアデノウイルスタンパク質をコードしない、請求項85に記載の方法。 89. 前記DNA分子がアデノウイルスITR配列、AAV ITR配列、転 写制御領域、ヒトFVIIIをコードする核酸、及びRep発現カセットを含み 、これらの全てが感染性複製不全組換えアデノウイルスベクターの生成に作用的 に関連し、該DNA分子の残部はアデノウイルスタンパク質をコードしない、請 求項87に記載の方法。 90. ヒトFVIIIに対して寛容化されている非ヒトトランスジェニック動 物の生成方法であって、 胚幹細胞にヒトFVIIIをコードする核酸及び薬剤選択マーカー遺伝子を含 むDNA分子を形質移入する工程; 該薬剤選択マーカー遺伝子によってコードされるタンパク質の発現により耐性 が付与される薬剤の存在下において該細胞を成長させることにより、そのゲノム 内に該DNA分子を含む胚幹細胞を選択する工程; 該胚幹細胞を胚盤胞に微量注入する工程; 該胚盤胞を仮母に移植する工程; 得られた子孫を飼育する工程; 該子孫を、該子孫のゲノム内の該ヒトFVIII遺伝子の存在について検定す る工程;及び 該ヒトFVIII遺伝子が検出されている子孫をホモ接合まで飼育する工程; を組み合わせて包含し、 それによりヒトFVIIIに対して寛容化されたトランスジェニック動物が生 じる方法。 91. 前記DNA分子が、合成プロモーター、発生的に調節されるプロモータ ー又は組織特異的プロモーターからなる群より選択されるプロモーターの転写制 御の下にヒトFVIII遺伝子を含む、請求項90に記載の方法。 92. 前記DNA分子が、α−胎児タンパク質プロモーター、アルブミンプロ モーター及びα−抗トリプシンプロモーターからなる群より選択されるプロモー ターの制御の下にヒトFVIII遺伝子を含む、請求項90に記載の方法。 93. 前記DNA分子が図58に示されるmAFP−hFVIII/pGKN eoを含む、請求項90に記載の方法。 94. 前記動物がマウスである、請求項90に記載の方法。 95. ヒトFVIII遺伝子を肝臓特異的プロモーターの転写制御の下に含む DNA分子を含む胚幹細胞であって、該DNA分子が薬剤選択マーカー遺伝子を さらに 含む胚幹細胞。 96. ヒトFVIIIに対して寛容化されているトランスジェニックマウス。 97. α−胎児タンパク質プロモーター、アルブミンプロモーター及びα−抗 トリプシンプロモーターからなる群より選択されるプロモーターの転写制御の下 に、そのゲノムに組み込まれているヒトFVIII遺伝子を有する、ヒトFVI IIに対して寛容化されているトランスジェニックマウス。 98. そのゲノムに組み込まれているDNA分子mAFP−hFVIII/p GKNeo又はそれらの断片を有するトランスジェニックマウス。 99. 緑色蛍光タンパク質に対して寛容化されている非ヒトトランスジェニッ ク動物の生成方法であって、 胚幹細胞に、合成プロモーター、組織特異的プロモーター及び発生的に調節さ れるプロモーターからなる群より選択されるプロモーターの転写制御の下に緑色 蛍光タンパク質遺伝子を含むDNA分子を形質移入する工程; 該薬剤選択マーカー遺伝子のタンパク質産生物の発現により耐性が付与される 薬剤の存在下において成長させることにより、そのゲノム内に該DNA分子を含 む胚幹細胞を選択する工程; 該胚幹細胞を胚盤胞に微量注入する工程; 該胚盤胞を仮母に移植する工程; 得られた子孫を飼育する工程; 該子孫を緑色蛍光タンパク質遺伝子配列の存在について検定する工程;及び そのゲノム内に緑色蛍光タンパク質遺伝子配列が検出されている子孫をホモ接 合まで飼育する工程; を組み合わせて包含し、 それにより緑色蛍光タンパク質に対して寛容化されたトランスジェニック動物 が生じる方法。 100. 前記動物がマウスである請求項99に記載の方法。 101. 前記組織特異的プロモーターが肝臓特異的である、請求項99に記載 の方法。 102. 前記組織特異的プロモーターがα−胎児タンパク質プロモーター、ア ルブミンプロモーター及びα1−抗トリプシンプロモーターからなる群より選択 される、請求項99に記載の方法。 103. 前記DNA分子が図62に示されるBS由来RIP−pEGFP及び 図60に示されるAFP−pEGFP−1からなる群より選択される、請求項9 9に記載の方法。 104. 緑色蛍光タンパク質に対して寛容化されているトランスジェニックマ ウス。 105. そのゲノムに安定に組み込まれている、図62に示されるBS由来R IP−pEGFP及び図60に示されるAFP−pEGFP−1からなる群より 選択されるDNA分子を有するトランスジェニックマウス。 106. そのゲノム内にAAVS1配列を含む非ヒトトランスジェニック緑色 蛍光タンパク質寛容化動物への、AAV−ITR及び緑色蛍光タンパク質遺伝子 を含むベクターのイン・ビボ送達を試験する方法であって、 該ベクターを該動物に注射する工程; 該動物から血液試料を単離し、該血液試料を緑色タンパク質の存在について分 析する工程; 該動物から肝臓組織を単離する工程; ポリメラーゼ連鎖反応(PCR)分析により、緑色蛍光タンパク質遺伝子配列 をコードする核酸の存在について該肝臓組織を分析する工程; 該肝臓組織の凍結切片を調製し、蛍光顕微鏡技術を用いて該凍結切片を緑色蛍 光タンパク質の存在について分析する工程; を組み合わせて包含し、 緑色蛍光タンパク質の存在は該トランスジェニック動物内で検出される方法。 107. 前記非ヒトトランスジェニック動物がマウスである、請求項106に 記載の方法。 108. 図42に示される、GT2074と呼ばれるDNA分子。 109. 図43に示される、pCMV−hFVIIIミニと呼ばれるDNA分 子。 110. 図60に示される、AFP−pEGFP−1と呼ばれるDNA分子。 111. 図58に示される、mAFP−hFVIII/pGKNeoと呼ばれ るDNA分子。 112. 図62に示される、BS由来RIP−pEGFPと呼ばれるDNA分 子。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65896196A | 1996-05-31 | 1996-05-31 | |
US08/658,961 | 1996-05-31 | ||
US79121897A | 1997-01-31 | 1997-01-31 | |
US08/791,218 | 1997-01-31 | ||
PCT/US1997/010218 WO1997045550A2 (en) | 1996-05-31 | 1997-05-30 | Mini-adenoviral vector |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004199828A Division JP2005000172A (ja) | 1996-05-31 | 2004-07-06 | ミニアデノウイルスベクター |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001502883A true JP2001502883A (ja) | 2001-03-06 |
Family
ID=27097728
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP09543095A Ceased JP2001502883A (ja) | 1996-05-31 | 1997-05-30 | ミニアデノウイルスベクター |
JP2004199828A Ceased JP2005000172A (ja) | 1996-05-31 | 2004-07-06 | ミニアデノウイルスベクター |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004199828A Ceased JP2005000172A (ja) | 1996-05-31 | 2004-07-06 | ミニアデノウイルスベクター |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0954591A2 (ja) |
JP (2) | JP2001502883A (ja) |
CA (1) | CA2257148A1 (ja) |
WO (1) | WO1997045550A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018019718A (ja) * | 2011-11-09 | 2018-02-08 | セダーズ−シナイ メディカル センター | 転写因子に基づくペースメーカー細胞の生成およびその使用方法 |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998023729A1 (en) | 1996-11-27 | 1998-06-04 | Anticancer, Inc. | In vitro model for hiv and other viral diseases |
US6403370B1 (en) | 1997-02-10 | 2002-06-11 | Genstar Therapeutics Corporation | Oncolytic/immunogenic complementary-adenoviral vector system |
US6251384B1 (en) | 1997-04-28 | 2001-06-26 | Anticancer, Inc. | Metastasis models using green fluorescent protein (GFP) as a marker |
US6232523B1 (en) | 1997-04-28 | 2001-05-15 | Anticancer, Inc. | Metastasis models using green fluorescent protein (GFP) as a marker |
CN1264429A (zh) | 1997-04-28 | 2000-08-23 | 抗癌股份有限公司 | 以绿荧光蛋白(gfp)为标记的肿瘤转移模型 |
AU7270198A (en) * | 1997-04-30 | 1998-11-24 | University Of Florida | Methods and materials for detection of gene transfer and expression |
WO1998054345A1 (en) * | 1997-05-30 | 1998-12-03 | Baxter International Inc. | Mini-adenoviral vector |
US20030044384A1 (en) | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
DE19807265C2 (de) * | 1998-02-20 | 2000-01-05 | Centeon Pharma Gmbh | Adenoviraler Transfervektor für den Gentransport einer DNA-Sequenz |
US6521426B1 (en) * | 1998-04-08 | 2003-02-18 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Preparation of recombinant adenovirus carrying a rep gene of adeno-associated virus |
GB9813670D0 (en) * | 1998-04-08 | 1998-08-26 | Angeletti P Ist Richerche Bio | Preparation of recombinant adenovirus carrying a rep gene of adeno-associated virus |
JP2004519201A (ja) | 1998-05-27 | 2004-07-02 | トランジェーヌ、ソシエテ、アノニム | キメラアデノウイルスベクター |
US6180108B1 (en) * | 1998-12-10 | 2001-01-30 | Bayer Corporation | Vectors having terminal repeat sequence of Epstein-Barr virus |
EP1390046A4 (en) * | 1999-04-15 | 2005-04-20 | Wellstat Biologics Corp | TREATMENT OF NEOPLASMS WITH VIRUSES |
EP1083229A1 (en) * | 1999-09-10 | 2001-03-14 | Introgene B.V. | Modified adenoviral vectors for use in gene therapy |
EP1083228A1 (en) * | 1999-09-10 | 2001-03-14 | Introgene B.V. | Modified adenoviral vectors for use in gene therapy |
CA2384439A1 (en) * | 1999-09-10 | 2001-03-22 | Crucell Holland B.V. | Modified adenoviral vectors for use in gene therapy |
US6541245B1 (en) | 1999-09-23 | 2003-04-01 | Genzyme Corporation | Adenoviral helper vectors |
WO2001021824A1 (en) * | 1999-09-23 | 2001-03-29 | Genzyme Corporation | Helper vectors and cell lines for the production of pseudoadenoviral vectors |
AU7879000A (en) * | 1999-10-12 | 2001-04-23 | University Of North Carolina At Chapel Hill, The | Adeno-associated virus vectors encoding factor viii and methods of using the same |
WO2002092786A2 (en) | 2001-03-26 | 2002-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | A helper dependent adenoviral vector system and methods for using the same |
US7238346B2 (en) * | 2002-07-08 | 2007-07-03 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | High capacity recombinant adenoviral vector for treatment of hemophilia A |
WO2005078848A2 (en) | 2004-02-11 | 2005-08-25 | University Of Tennessee Research Foundation | Inhibition of tumor growth and invasion by anti-matrix metalloproteinase dnazymes |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5470560A (en) * | 1987-01-20 | 1995-11-28 | Genentech, Inc. | Method for evaluating immunogenicity |
AU2661692A (en) * | 1991-09-19 | 1993-04-27 | President And Fellows Of Harvard College | Transgenic mhc class i and class ii antigen-deficient mammals |
CA2106260A1 (en) * | 1992-09-17 | 1994-03-18 | Robert M. Kotin | Human adeno-associated virus integration site dna and uses thereof |
AU680459B2 (en) * | 1992-12-03 | 1997-07-31 | Genzyme Corporation | Gene therapy for cystic fibrosis |
FR2705686B1 (fr) * | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
WO1994029471A1 (en) * | 1993-06-10 | 1994-12-22 | Genetic Therapy, Inc. | Adenoviral vectors for treatment of hemophilia |
FR2716893B1 (fr) * | 1994-03-03 | 1996-04-12 | Rhone Poulenc Rorer Sa | Virus recombinants, leur préparation et leur utilisation thérapeutique. |
DK0787200T3 (da) * | 1994-10-28 | 2005-08-15 | Univ Pennsylvania | Forbedret adenovirus og fremgangsmåder til anvendelse heraf |
CA2218610A1 (en) * | 1995-04-17 | 1996-10-24 | Board Of Regents, The University Of Texas System | An adenovirus helper-virus system |
JPH11514853A (ja) * | 1995-09-08 | 1999-12-21 | ジエンザイム コーポレイション | 遺伝子治療のための改良されたaavベクター |
-
1997
- 1997-05-30 WO PCT/US1997/010218 patent/WO1997045550A2/en not_active Application Discontinuation
- 1997-05-30 EP EP97928961A patent/EP0954591A2/en not_active Withdrawn
- 1997-05-30 JP JP09543095A patent/JP2001502883A/ja not_active Ceased
- 1997-05-30 CA CA002257148A patent/CA2257148A1/en not_active Abandoned
-
2004
- 2004-07-06 JP JP2004199828A patent/JP2005000172A/ja not_active Ceased
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018019718A (ja) * | 2011-11-09 | 2018-02-08 | セダーズ−シナイ メディカル センター | 転写因子に基づくペースメーカー細胞の生成およびその使用方法 |
US10973876B2 (en) | 2011-11-09 | 2021-04-13 | Cedars-Sinai Medical Center | Transcription factor-based generation of pacemaker cells and methods of using same |
Also Published As
Publication number | Publication date |
---|---|
JP2005000172A (ja) | 2005-01-06 |
CA2257148A1 (en) | 1997-12-04 |
EP0954591A2 (en) | 1999-11-10 |
WO1997045550A2 (en) | 1997-12-04 |
WO1997045550A3 (en) | 1998-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001502883A (ja) | ミニアデノウイルスベクター | |
US6156497A (en) | Recombinase-mediated generation of adenoviral vectors | |
US6403370B1 (en) | Oncolytic/immunogenic complementary-adenoviral vector system | |
JP3565859B2 (ja) | 改良されたアデノウイルスおよびその使用法 | |
US7195896B2 (en) | Complementary adenoviral vector systems and cell lines | |
KR100379654B1 (ko) | 동물세포의형질감염을위한재조합dna바이러스벡터 | |
Mitani et al. | Adenovirus as an integrating vector | |
WO1997025446A9 (en) | Recombinase-mediated generation of adenoviral vectors | |
JPH10507061A (ja) | アデノウイルス中にパッケージされたプラスミドdnaを用いる遺伝子送達ベクターおよびパッケージング細胞株 | |
WO1998035028A9 (en) | An oncolytic/immunogenic complementary-adenoviral vector system | |
JPH09509578A (ja) | 組み込み可能な組み換えアデノウィルス、それらの製造及びそれらの治療的利用 | |
JPH11507240A (ja) | 組み換えアデノウイルス及びアデノ随伴ウイルス、細胞株、並びに生産方法並びにその使用 | |
US8883493B2 (en) | Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene | |
JP2001520050A (ja) | 遺伝子供給ベクター類及びそれらの使用 | |
JP4386971B2 (ja) | スプライシング配列を含んでなる組換えアデノウイルスベクター | |
US20030017597A1 (en) | Hybrid vectors for gene therapy | |
US20030192066A1 (en) | Minimal adenoviral vector | |
JPH10510995A (ja) | 胚細胞発現のためのレトロウイルスベクター | |
Ponder | Vectors in gene therapy | |
WO2002008436A2 (en) | Mini-adenoviral vector system for vaccination | |
US20040208846A1 (en) | Mini-Ad vector for immunization | |
US20020088014A1 (en) | Minimal adenovirus mediated recombinant vaccine | |
WO2002085287A2 (en) | Minimal adenoviral vectors for immunization | |
CZ296600B6 (cs) | Virový vektor obsahující replikující se DNA, zpusob prípravy této DNA a farmaceutická kompozice obsahující virový vektor | |
JP4159620B2 (ja) | 組換えアデノウイルスの製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040406 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040517 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040706 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051004 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20060220 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060328 |